eLife (Aug 2024)
Antibody characterization is critical to enhance reproducibility in biomedical research
- Richard A Kahn,
- Harvinder Virk,
- Carl Laflamme,
- Douglas W Houston,
- Nicole K Polinski,
- Rob Meijers,
- Allan I Levey,
- Clifford B Saper,
- Timothy M Errington,
- Rachel E Turn,
- Anita Bandrowski,
- James S Trimmer,
- Meghan Rego,
- Leonard P Freedman,
- Fortunato Ferrara,
- Andrew RM Bradbury,
- Hannah Cable,
- Skye Longworth
Affiliations
- Richard A Kahn
- ORCiD
- Department of Biochemistry, Emory University School of Medicine, Atlanta, United States
- Harvinder Virk
- ORCiD
- Department of Respiratory Sciences, University of Leicester, Leicester, United Kingdom
- Carl Laflamme
- ORCiD
- Department of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Canada
- Douglas W Houston
- ORCiD
- The Development Studies Hybridoma Databank, University of Iowa, Iowa City, United States
- Nicole K Polinski
- ORCiD
- The Michael J Fox Foundation for Parkinson’s Research, New York, United States
- Rob Meijers
- Institute for Protein Innovation, Boston, United States
- Allan I Levey
- ORCiD
- Department of Neurology, Emory University School of Medicine, Atlanta, United States
- Clifford B Saper
- Department of Neurology and Program in Neuroscience, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, United States
- Timothy M Errington
- ORCiD
- Center for Open Science, Charlottesville, United States
- Rachel E Turn
- ORCiD
- Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, United States
- Anita Bandrowski
- ORCiD
- Department of Neuroscience, University of California, San Diego, La Jolla, United States
- James S Trimmer
- ORCiD
- Department of Physiology and Membrane Biology, University of California, Davis School of Medicine, Davis, United States
- Meghan Rego
- Addgene, Watertown, United States
- Leonard P Freedman
- ORCiD
- Frederick National Laboratory for Cancer Research, Frederick, United States
- Fortunato Ferrara
- Specifica, a Q2 company, Santa Fe, United States
- Andrew RM Bradbury
- Specifica, a Q2 company, Santa Fe, United States
- Hannah Cable
- ORCiD
- Department of Research and Development, Abcam, Cambridge, United Kingdom
- Skye Longworth
- CiteAb, Bath, United Kingdom
- DOI
- https://doi.org/10.7554/eLife.100211
- Journal volume & issue
-
Vol. 13
Abstract
Antibodies are used in many areas of biomedical and clinical research, but many of these antibodies have not been adequately characterized, which casts doubt on the results reported in many scientific papers. This problem is compounded by a lack of suitable control experiments in many studies. In this article we review the history of the ‘antibody characterization crisis’, and we document efforts and initiatives to address the problem, notably for antibodies that target human proteins. We also present recommendations for a range of stakeholders – researchers, universities, journals, antibody vendors and repositories, scientific societies and funders – to increase the reproducibility of studies that rely on antibodies.
Keywords